USPTO serial 87900878
ARINGAGE
Reviewed by CopyMark Law Group
Reg. 5970134Status 710
- Filing date
- Status date
- Registration date
- Jan 28, 2020
- Examiner
- FATHY, DOMINIC
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ARINGAGE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Gangnam-gu, Seoul, KR
Gangnam-gu, Seoul, KR
Gangnam-gu, Seoul, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Davis Graham & Stubbs LLC3400 Walnut Street, Suite 700Denver, CO 80205United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; sanitary preparations for medical purposes; biotechnological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; biological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; drugs for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; pharmaceuticals for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; multivitamins preparations; pharmaceutical preparations for diagnosis for medical orveterinary purposes; nutraceutical preparations for therapeutic or medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; preparations of microorganisms for medical and veterinary use for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease; antibiotics | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CMG Pharmaceutical Co.,Ltd.
- Other trademarks owned by CMG Pharmaceutical Co.,Ltd.
- Other trademarks owned by CMG Pharmaceutical Co.,Ltd.
- Other trademarks in Class 005
- Similar marks named ARINGAGE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 7, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 28, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Nov 14, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 14, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 14, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 14, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 28, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 12, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 12, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 23, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 5, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 25, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 25, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 11, 2019 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 11, 2019 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 11, 2019 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 1, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 26, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Mar 12, 2019 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Mar 8, 2019 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Mar 6, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 25, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 7, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 21, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 9, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 3, 2018 | NWAP | NEW APPLICATION ENTERED | — |